A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination with Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
ARCADIAN: Atovaquone with Radical ChemorADIotherapy in locally Advanced NSCLC
The ARCADIAN trial has received Green Light approval from OCTRU and subsequently opened to recruitment at its first site in Oxford.
Funded by CRUK, ARCADIAN aims to investigate whether the drug atovaquone can be safely given to patients undergoing chemoradiotherapy for Non-Small Cell Lung Cancer (NSCLC).
Atovaquone has previously been shown to reduce tumour hypoxia, a state which can cause resistance to traditional cancer treatments. If the study shows that it is safe to administer atovaquone with chemoradiotherapy, further studies would be planned to assess the efficacy of this combination treatment.
Find out more on the Department of Oncology website: https://www.oncology.ox.ac.uk/about-us/overview/clinical-trials/clinical-trial-portfolio/arcadian.